Back to homepage

Tag "vulvar and vaginal atrophy"

Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles

Authors: María del Carmen Pingarrón Santofimia MD, Silvia Pilar González Rodríguez MD, PhD, Mariella Lilue MD, Santiago Palacios MD, PhD

In this case report, outcomes in relation to bone homeostasis, bone mineral density (BMD), and osteopenia– osteoporosis are examined in postmenopausal women during treatment with ospemifene for vulvar and vaginal atrophy (VVA), a component of the genitourinary syndrome of menopause.

More

Ospemifene for vulvar and vaginal atrophy: an overview

Authors: Santiago Palacios MD, PhD

This editorial article introduces a Special Focus Issue entitled “Treatment of Vulvar and Vaginal Atrophy: Clinical Experience with Ospemifene”. Ospemifene is a selective estrogen receptor modulator indicated for treatment of moderate-to-severe symptomatic vulvar and vaginal atrophy in postmenopausal women who are not candidates for local vaginal estrogen therapy or have contraindications for estrogen products.

More